J B Chemicals & Pharmaceuticals Ltd News
JB Chem, Divis Labs among top stock recommendations by Vinay Rajani
Vinay Rajani of HDFC Securities says Divis Labs share price has broken out from the box pattern on the daily chart with the primary trend of the stock staying bullish
 "JB Chem, Divis Labs among top stock recommendations by Vinay Rajani")
JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains
Domestic, CDMO and API businesses drive growth for JB Pharma in Q1FY26 as Razel crosses Rs 100 crore and ophthalmology portfolio sees 19 per cent expansion
 "JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains")
JB Pharma Q1 results: Net profit up at 14% to ₹202 cr, revenue rises 9%
JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 14 per cent rise in net profit to Rs 202 crore in the June quarter. The company had posted a net profit of Rs 177 crore in the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals (JB Pharma) said in a regulatory filing. Revenue in the first quarter stood at Rs 1,094 crore as against Rs 1,004 crore in the same period a year ago, up 9 per cent, it added. "The domestic business recorded approximately 14 per cent value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well," JB Pharma CEO and Wholetime Director, Nikhil Chopra said. He further said, "The CDMO (contract development and manufacturing organisation) business momentum is likely to sustain in coming quarters." The company said its domestic formulations business recorded revenue of Rs 678 crore as against Rs 595 crore in the first ...
 "JB Pharma Q1 results: Net profit up at 14% to ₹202 cr, revenue rises 9%")